Paul Hastings LLP, a leading global law firm, announced today that the firm advised BioMarin Pharmaceutical Inc., a pharmaceutical company that develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, in connection with its underwritten offering of 6,500,000 shares of common stock. In connection with launching the offering BioMarin estimated the offering would raise gross proceeds of approximately $249 million before costs.

BofA Merrill Lynch and Barclays acted as the underwriters in the offering.

Securities & Capital Markets partner Thomas Pollock led the Paul Hastings team, which also included corporate associates Samantha Eldredge and Aliza Cohen.


Related Posts:

Leave a Reply